A genetic variant in the promoter region of miR-106b-25 cluster predict clinical outcome of HBV-related hepatocellular carcinoma in Chinese

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Qi, Fuzhen ^a   Huang, Mingde ^a   Pan, Yun ^a   Liu, Yao ^a   Liu, Jibin ^b   Wen, Juan ^a   Xie, Kaipeng ^a   Shen, Hongbing ^a   Ma, Hongxia ^a   Miao, Yi ^a   Hu, Zhibin ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b NANTONG TUMOR HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 106 25; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CHINESE; FEMALE; GENE CLUSTER; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HEPATITIS B VIRUS; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PROMOTER REGION; REGRESSION ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM;

ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, HEPATOCELLULAR; FEMALE; HEPATITIS B; HUMANS; INTRONS; LIVER NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; MINICHROMOSOME MAINTENANCE COMPLEX COMPONENT 7; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS;

EID: 84896915320     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0085394     Document Type: Article

References (42)

1. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP (2006) The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 45: 529-538. (Pubitemid 44307383)
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
3. Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297.
4. Braconi C, Henry JC, Kogure T, Schmittgen T, Patel T (2011) The role of microRNAs in human liver cancers. Semin Oncol 38: 752-763.
5. Toffanin S, Hoshida Y, Lachenmayer A, Villanueva A, Cabellos L, et al. (2011) MicroRNA-based classification of hepatocellular carcinoma and oncogenicrole of miR-517a. Gastroenterology 140: 1618-1628.
6. Hou J, Lin L, Zhou W, Wang Z, Ding G, et al. (2011) Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer Cell 19: 232-243.
7. Li J, Wang Y, Yu W, Chen J, Luo J (2011) Expression of serum miR-221 in human hepatocellula rcarcinoma and its prognostic significance. Biochem Biophys Res Commun 406: 70-73.
8. Gao P, Wong CC, Tung EK, Lee JM, Wong CM, et al. (2011) Deregulation of microRNA expression occurs early and accumulates in early stages of HBV-associated multistep hepatocarcinogenesis. J Hepatol 54: 1177-1184.
9. Li Y, Tan W, Neo TW, Aung MO, Wasser S, et al. (2009) Role of the miR-106b-25 microRNA cluster in hepatocellular carcinoma. Cancer Sci 100: 1234-1242.
10. Varnholt H, Drebber U, Schulze F, Wedemeyer I, Schirmacher P, et al. (2008) MicroRNA gene expression profile of hepatitis C virus-associated hepatocellular carcinoma. Hepatology 47: 1223-32. (Pubitemid 351547908)
11. Wong CC, Wong CM, Tung EK, Au SL, Lee JM, et al. (2011) The MicroRNA miR-139 Suppresses Metastasis and Progression of Hepatocellular Carcinoma by Down-regulating Rho-Kinase 2. Gastroenterology 140: 322-331.
12. Li W, Xie L, He X, Li J, Tu K, et al. (2008) Diagnostic and prognostic implications of microRNAs in human hepatocellular carcinoma. Int J Cancer 123: 1616-1622.
13. Ladeiro Y, Couchy G, Balabaud C, Bioulac-Sage P, Pelletier L, et al. (2008) MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology 47: 1955-1963. (Pubitemid 351952843)
14. Wong QW, Lung RW, Law PT, Lai PB, Chan KY, et al. (2008) MicroRNA-223 is commonly repressed in hepatocellular carcinoma and potentiates expression of Stathmin1. Gastroenterology 135: 257-269. (Pubitemid 351910680)
15. Jiang J, Gusev Y, Aderca I, Mettler TA, Nagorney DM, et al. (2008) Association of MicroRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. Clin Cancer Res14: 419-427. (Pubitemid 351226109)
16. Cai K, Wang Y, Bao X (2011) MiR-106b promotes cell proliferation via targeting RB in laryngeal carcinoma. J Exp Clin Cancer Res 30: 73.
17. Li B, Shi XB, Nori D, Chao CK, Chen AM, et al. (2011) Down-regulation of microRNA 106b is involved in p21-mediated cell cycle arrest in response to radiation in prostate cancer cells. Prostate 71: 567-574.
18. Slaby O, Jancovicova J, Lakomy R, Svoboda M, Poprach A, et al. (2010) Expression of miRNA-106b in conventional renal cell carcinoma is a potential marker for prediction of early metastasis after nephrectomy. J Exp Clin Cancer Res 29: 90.
19. Ivanovska I, Ball AS, Diaz RL, Magnus JF, Kibukawa M, et al. (2008) MicroRNAs in the miR-106b family regulate p21/CDKN1A and promote cell cycle progression. Mol Cell Biol 28: 2167-2174. (Pubitemid 351429964)
20. Shen G, Jia H, Tai Q, Li Y, Chen D (2013) miR-106b downregulates adenomatous polyposis coli and promotes cell proliferation in human hepatocellular carcinoma. Carcinogenesis 34: 211-219.
21. Lovat F, Valeri N, Croce CM (2011) MicroRNAs in the pathogenesis of cancer. Semin Oncol 38: 724-733.
22. Liu Y, Zhang Y, Wen J, Liu L, Zhai X, et al. (2012) A genetic variant in the promoter region of miR-106b-25 cluster and risk of HBV infection and hepatocellular carcinoma. PLoS One 7: e32230.
23. Hu L, Zhai X, Liu J, Chu M, Pan S, et al. (2012) Genetic variants in human leukocyte antigen/DP-DQ influence both hepatitis B virus clearance and hepatocellular carcinoma development. Hepatology 55: 1426-1431.
24. Xie K, Liu J, Zhu L, Liu Y, Pan Y, et al. (2013) A potentially functional polymorphism in the promoter region of let-7 family is associated with survival of hepatocellular carcinoma. Cancer Epidemiol pii: S1877-7821(13)00147-1.
25. Gómez-Rodríguez R, Romero-Gutiérrez M, Artaza-Varasa T, González-Frutos C, Ciampi-Dopazo JJ, et al. (2012) The value of the Barcelona Clinic Liver Cancer and alpha-fetoprotein in the prognosis of hepatocellular carcinoma. Rev Esp Enferm Dig 104: 298-304.
26. Hui AB, Lenarduzzi M, Krushel T, Waldron L, Pintilie M, et al. (2010) Comprehensive MicroRNA profiling for head and neck squamous cell carcinomas. Clin Cancer Res 16: 1129-1139.
27. Kan T, Meltzer SJ (2009) MicroRNAs in Barrett's esophagus and esophageal adenocarcinoma. Curr Opin Pharmacol 9: 727-732.
28. Guo J, Miao Y, Xiao B, Huan R, Jiang Z, et al. (2009) Differential expression of microRNA species in human gastric cancer versus non-tumorous tissues. J Gastroenterol Hepatol 24: 652-657.
29. Namløs HM, Meza-Zepeda LA, Barøy T, Østensen IH, Kresse SH, et al. (2012) Modulation of the osteosarcoma expression phenotype by microRNAs. PLoS One 7: e48086.
30. Landgraf P, Rusu M, Sheridan R, Sewer A, Iovino N, et al. (2007) A Mammalian microRNA expression atlas based on small RNA library sequencing. Cell 129: 1401-1414. (Pubitemid 46970709)
31. Ivanovska I, Ball AS, Diaz RL, Magnus JF, Kibukawa M, et al. (2008) MicroRNAs in the miR-106b family regulate p21/CDKN1A and promote cell cycle progression. Mol Cell Biol 28: 2167-2174. (Pubitemid 351429964)
32. Savita U, Karunagaran D (2013) MicroRNA-106b-25 cluster targets β-TRCP2, increases the expression of Snail and enhances cell migration and invasion in H1299 (Non Small Cell Lung Cancer) cells. Biochem Biophys Res Commun 434: 841-847.
33. Hu Z, Shu Y, Chen Y, Chen J, Dong J, et al. (2011) Genetic polymorphisms in the precursor MicroRNA flanking region and non-small cell lung cancer survival. Am J Respir Crit Care Med 183: 641-648.
34. Tian T, Shu Y, Chen J, Hu Z, Xu L, et al. (2009) A functional genetic variant in microRNA-196a2 is associated with increased susceptibility of lung cancer in Chinese. Cancer Epidemiol Biomarkers Prev 18: 1183-1187.
35. Xu Y, Liu L, Liu J, Zhang Y, Zhu J, et al. (2011) A potentially functional polymorphism in the promoter region of miR-34b/c is associated with an increased risk for primary hepatocellular carcinoma. Int J Cancer 128: 412-417.
36. Wang L, Wu XP, Zhang W, Zhu DH, Wang Y, et al. (2011) Evaluation of genetic susceptibility loci for chronic hepatitis B in Chinese: two independent case-control studies. PLoS One 6: e17608.
37. Zhong R, Tian Y, Liu L, Qiu Q, Wang Y, et al. (2012) HBV-related hepatocellular carcinoma susceptibility gene KIF1B is not associated with development of chronic hepatitis B. PLoS One 7: e28839.
38. Anders G, Mackowiak SD, Jens M, Maaskola J, Kuntzagk A, et al. (2012) doRiNA: a database of RNA interactions in post-transcriptional regulation. Nucleic Acids Res 40(Database issue): D180-186.
39. Chen H, Hao Y, Wang L, Jia D, Ruan Y, et al. (2012) Sodium arsenite downregulates the expression of X-linked inhibitor of apoptosis protein via translational and post-translational mechanisms in hepatocellular carcinoma. Biochem Biophys Res Commun 422: 721-726.
40. Chan SL, Mo FK, Johnson PJ, Hui EP, Ma BB, et al. (2009) New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy. J Clin Oncol 27: 446-452.
41. Chon YE, Choi GH, Lee MH, Kim SU, Kim do Y, et al. (2012) Combined measurement of preoperative a-fetoprotein and des- c-carboxy prothrombin predicts recurrence after curative resection in patients with hepatitis-B-related hepatocellular carcinoma. Int J Cancer 131: 2332-2341.
42. Lee YK, Kim SU, Kim do Y, Ahn SH, Lee KH, et al. (2013) Prognostic value of a- fetoprotein and des-c-carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolization. BMC Cancer 3; 13: 5.